Cardiol Therapeutics closes $10.5 million private placement

1 minute read
24 May 2018
Client work

On May 24, 2018, Cardiol Therapeutics Inc. ("Cardiol") announced the successful closing of a brokered private placement of approximately $10.5 million principal amount of unsecured convertible debentures of the company. AltaCorp Capital Inc. acted as exclusive financial advisor to Cardiol and sole agent on the private placement. 

Cardiol is a nanotherapeutics company focused on advancing the treatment of heart failure by developing proprietary formulations designed to deliver cannabinoids and other drugs to inflamed tissue in the heart. 

Gowling WLG advised Cardiol with respect to this private placement with a team that included Brett Kagetsu, Denis Silva, Bahar Hafizi, Bryce Kraeker and Tara Amiri-Khaledi, assisted by paralegal Toni Vodola. 

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences, Capital Markets

Related Insights & Resources

View all insights Related Insights & Resources
Client work
14 March 2024 Innocan Pharma closes non-brokered private placement
paperclip chain Articles
31 January 2024 Supply chain transparency reporting begins in Canada
Client work
05 January 2024 NurExone Biologic Inc. closes private placement financing
Download or print PDF